H.C. Wainwright analyst Yi Chen raised the firm’s price target on Oculis (OCS) to $36 from $33 and keeps a Buy rating on the shares. The firm says privosegtor may be priced above $100,000 per treatment if successfully developed and approved.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS:
- Oculis Advances Privosegtor into Registrational Trials for Neuro-Ophthalmology
- Oculis Holding: Strategic Advancements and Market Potential Drive Buy Rating
- Oculis initiated with a Buy at Needham
- Nvidia reportedly stops H20 AI chip output for China: Morning Buzz
- Oculis price target raised to $33 from $32 at H.C. Wainwright